Methomol 750 mg

Methomol 750 mg | INDICATIONS AND USES

Methocarbamol tablet is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

Methomol 750 mg | PHARMACOLOGY

The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity. This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells. Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.

Methomol 750 mg | DOSAGE & ADMINISTRATION

Route of Administration: OralMethocarbamol 500 mg- Adults:

Initial dosage: 3 tablets q.i.d.
Maintenance dosage: 2 tablets q.i.d.

Methocarbamol 750 mg- Adults:

Initial dosage: 2 tablets q.i.d.
Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment (for severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.Pediatric Use: Safety and effectiveness of Methocarbamol in pediatric patients below the age of 16 have not been established.

Methomol 750 mg | DRUG INTERACTIONS

Methocarbamol may inhibit the effect of Pyridostigmine Bromide. Therefore, Methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.Drug/Laboratory Test Interactions: Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate the carcinogenic potential of Methocarbamol have not been performed. No studies have been conducted to assess the effect of Methocarbamol on mutagenesis or its potential to impair fertility.

Methomol 750 mg | SIDE EFFECTS

Adverse reactions reported coincident with the administration of methocarbamol include:Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headacheCardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombo- phlebitisDigestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomitingHemic and lymphatic system: LeukopeniaImmune system: Hypersensitivity reactionsNervous system: Amnesia, confusion, Diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigoSkin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria.

Methomol 750 mg | USE DURING PREGNANCY AND LACTATION

Pregnancy Category C. Animal reproduction studies have not been conducted with Methocarbamol. It is also not known whether Methocarbamol can cause fetal harm when adminis- tered to a pregnant woman or can affect reproduction capacity. Methocarbamol should be given to a pregnant woman only if clearly needed. Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether Methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol is administered to a nursing woman.

Methomol 750 mg | PRECAUTIONS & WARNINGS

Patients should be cautioned that Methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery because Methocarbamol may possess a general CNS-depressants effect. Patients should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards.

Methomol 750 mg | THERAPEUTIC CLASS

Centrally acting Skeletal Muscle Relaxants

Methomol 750 mg | STORAGE CONDITIONS

Protect from light, store below 30°C. Keep the medicine out of the reach of children.